The UK MHRA has completed investigations into pharmaceutical advertisements reported as breaching advertising legislation in June 2026. Thes… #Consumerprotection #Medicinesregulation #MHRA #Pharmaceuticaladvertising #UKhealthcarepolicy

From an Indian innovation to a global renal-care opportunity: Lord’s Mark Industries takes its AI-powered dialysis ecosystem closer to international markets. In a landmark moment for India’s medical technology sector, Lord’s Mark Industries Limited, through its healthcare and med-tech platform, has secured registration with the Medicines & Healthcare products Regulatory Agency (MHRA), London, UK, for its haemodialysis system, marking a major step towards taking its AI-powered dialysis technology and integrated renal-care ecosystem to the UK and UK-allied markets. The company positions this milestone as India’s first and the world’s first such AI-powered dialysis ecosystem to secure the regulatory milestone at this pace, and as the first Indian company to achieve this milestone in the context of the India-UK Free Trade Agreement (FTA). The registration covers Renalyx Health Systems Pvt. Ltd. as a manufacturer, with its haemodialysis system for institutional and home use registered under GMDN Code 58131. Lord’s Mark Industries Limited will start exporting its machine to Uk and Uk ally countries from early January 2027. What began as a Made-in-India medical technology is now stepping onto the global healthcare stage. Lord’s Mark Industries is taking its world-first AI-powered integrated dialysis ecosystem beyond India, with the UK emerging as a...

The UK MHRA has published guidance enabling pharmaceutical manufacturers to submit non-safety-critical changes to drug labels and Patient Inform… #Druglabelling #MHRA #Patientinformation #Pharmaceuticalregulation #Qualityassurance

Avacopan Vifor is used in the treatment of some rare autoimmune diseases affecting small blood vessels.

Following convictions related to falsely certified medical devices, the MHRA has welcomed the sentencing in a long-running enforcement investigation.

Advice has been issued to care home staff about using a filter when administering parenteral nutrition following ‘adverse incidents’.

Following convictions related to falsely certified medical devices, the MHRA has welcomed the sentencing in a long-running enforcement investigation.

🚨 URGENT: UK medicines regulator (MHRA) has issued a Class 4 alert for Gabapentin Relonchem 50mg/ml Oral Solution due to particles found in bottle… #Gabapentin #MHRAalert #PatientSafety #Pharmaceuticalsafety #Qualitydefect

<img src="https://www.govwire.co.uk/og/cache/news/2738897.png"/>Following convictions related to falsely certified medical devices, the MHRA has welcomed the sentencing in a long-running enforcement investigation. | Medicines and Healthcare products Regulatory Agency.

Following extensive engagement, an independent expert commission led by doctors working in the NHS has published a blueprint for the regulation of AI in healthcare.

A National Patient Safety Alert has been issued setting out practical steps to reduce the risk of harm when using patient hoists through improved checks and maintenance.

<p>MHRA issues national safety alert over risk of death and serious harm from patient hoists The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a National Patient Safety Alert…

Pulsenmore (PLSM) has completed registration of its Pulsenmore FC home fertility ultrasound system with the UK MHRA, allowing marketing across the United Kingdom and Northern Ireland.Pulsenmore FC supports women undergoing IVF and fertility preservation by enabling self‑performed vaginal ultrasound scans at home, with remote professional guidance, to monitor follicular development and endometrial thickness. The UK fertility market includes about 53,000 IVF patients and more than 100,000 fertility and storage cycles in 2024. This is Pulsenmore's second product in international markets and extends the company's platform from pregnancy monitoring into the broader women's health and fertility segment, with plans to expand Pulsenmore FC into additional countries.

A National Patient Safety Alert has been issued setting out practical steps to reduce the risk of harm when using patient hoists through improved checks and maintenance.

<img src="https://www.govwire.co.uk/og/cache/news/2677464.png"/>A National Patient Safety Alert has been issued setting out practical steps to reduce the risk of harm when using patient hoists through improved checks and maintenance. | Medicines and Healthcare products Regulatory Agency.

The MHRA has reaffirmed its commitment to strengthening regulatory collaboration with Malaysia following high-level discussions in Kuala Lumpur.

Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submissionsFull alignment achieved on confirmatory Phase 3 trial designComplete CMAA submission expected in coming weeksNew York, New York and Rockville, Maryland--(Newsfile Corp. - September 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has achieved full alignment with...

<img src="https://www.govwire.co.uk/og/cache/news/2668734.png"/>The MHRA has reaffirmed its commitment to strengthening regulatory collaboration with Malaysia following high-level discussions in Kuala Lumpur. | Medicines and Healthcare products Regulatory Agency.

Introduced in the government’s Health Bill, they aim to support information sharing, regulatory reform and the future development of a medical device licensing regime.

CAMP4 Therapeutics has secured MHRA authorisation to include UK sites in its global Phase 1/2 study of CMP-002, an ASO targeting SYNGAP1-related

The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme

The technology will soon be routinely used within the NHS, MHRA chief Lawrence Tallon tells the BBC.

A consultation on the Medicines and Healthcare products Regulatory Authority’s (MHRA) proposed rare disease therapies regulatory framework has...